Professional Services Inc. operating as The Medical City (TMC) is a health institution in the Philippines which maintains a network of hospitals and clinics in the Philippines. The TMC also maintains the Guam Regional Medical City in Guam and a network of clinics in the Gulf states.
INTRODUCTION:Artificial intelligence (AI) and digital pathology have the potential to augment liver biopsy interpretation in MAFLD in clinical practice and trials assessment. However, attitudes and barriers to its implementation have not been systematically explored. METHODS:A survey focusing on conventional liver histology, digital pathology and its AI applications in MAFLD/MASH was conducted among hepatologists and liver pathologists in the Asia Pacific region. RESULTS:AI-assisted digital pathology is perceived to be a valuable addition to existing histological reporting in MAFLD/MASH. Defined standards for application and validation of AI models are important priorities for their implementation. CONCLUSION:There is consensus among clinical experts in the Asia Pacific that AI-assisted histological assessment is useful in MAFLD/MASH interpretation. However, there remain important challenges to the adoption of these technologies into routine clinical workflows.
Background: Mammographic imaging is fundamental for breast cancer detection, revealing diverse tumor characteristics. Advances in molecular profiling have deepened understanding of tumor biology and diagnostic implications. Objective: This study aimed to examine the relation between mammographic findings of malignant breast masses and their molecular characteristics in patients with breast cancer. Methodology: Fifty-one female patients were enrolled at an oncology teaching hospital from November 2024 to February 2025. Standardized mammographic imaging was performed with two experienced radiologists independently interpreting the images and documenting features. Tissue samples, were analyzed by senior pathologists using immunohistochemical staining to evaluate estrogen receptor and human epidermal growth factor receptor expression. Results: The mean age of patients was 54.7 years. Over half of the masses exhibited speculation (51.0%), with microcalcifications and architectural distortion present in 37.3% and 43.1% of cases. Molecular analysis revealed that 51.0% of tumors were estrogen receptor positive and human epidermal growth factor receptor negative, followed by 23.5% with both receptors positive, 21.6% with human epidermal growth factor receptor positive and estrogen receptor negative, and 3.9% with both receptors negative. A significant association was found between microcalcifications and molecular subtype (p = 0.003). Microcalcifications were significantly linked to aggressive breast cancer subtypes, particularly HER2-positive and triple-negative cases. Conclusion: The high prevalence of estrogen receptor-positive and human epidermal growth factor receptor-negative tumors reinforces the importance of mammographic screening in early detection. Bangladesh Journal of Infectious Diseases, June 2026;13(1):188-195
Background and Objectives:Migraine is a significant disabling neurologic headache disorder globally. Evaluating patient-related outcomes (PROs) is necessary to assess the impact of therapeutic interventions in preventive therapy. An exploratory analysis of data from the EMPOwER study examined the effect of erenumab on PROs in patients with episodic migraine (EM) in regions underrepresented in the pivotal Phase 3 trials of erenumab, specifically Asia, the Middle East, and Latin America. Methods:Patients (N = 900) were randomized (2:3:3) to receive monthly subcutaneous injections of erenumab 140 mg, erenumab 70 mg, or placebo. Adjusted mean changes from baseline in the Headache Impact Test (HIT-6), Migraine Physical Function Impact Diary (MPFID), modified Migraine Disability Assessment (mMIDAS), and EuroQoL 5-dimension 5-level scale (EQ-5D-5L) scores were assessed during the double-blind treatment phase of 3 months. Results:A statistically significant reduction from baseline in the HIT-6 total score was observed for erenumab 140 mg (-9.34, p < 0.001) and 70 mg (-8.39, p = 0.004) vs placebo (-6.62) at Month 3. Improvement in MPFID scores was also greater in the erenumab groups vs the placebo group (Everyday Activity: 140 mg, -5.61 [p = 0.002]; 70 mg, -4.94 [p = 0.011]; placebo, -3.19; Physical Impairment: 140 mg, -4.27 [p = 0.014]; 70 mg, -3.95 [p = 0.021]; placebo, -2.31) at Month 3. Similar findings were observed for mMIDAS scores (140 mg -8.99 [p < 0.001], 70 mg -8.11 [p = 0.011] vs placebo [-6.59]) and the EQ-5D-5L quality-of-life visual analog scale scores (140 mg 8.13 [p = 0.017], 70 mg 7.08 [p = 0.088] vs placebo [5.22]), although no meaningful between-group difference was noted for index values. Discussion:Erenumab showed favorable effects on PROs when compared with placebo in patients with EM. These results enhance the evidence for erenumab as an effective preventive therapy for patients with EM. Trial Registration Information:Clinicaltrials.gov/study/NCT03333109.
Objective: To evaluate cone- and rod-specific nonperfusion indices (CPI, RPI) on ultrawide field fluorescein angiography (UWF-FA) and their correlation with diabetic retinopathy (DR) severity and center-involving diabetic macular edema (ciDME). Methods Sixty-nine eyes of 43 patients with diabetes underwent UWF color photography (UWF-CP), UWF-FA, and macular optical coherence tomography (OCT). DR severity was graded by a masked reader on UWF-CP. UWFFA images were segmented into posterior pole (≤10 mm from fovea), mid-periphery (10–15 mm) and far periphery (>15 mm), and into the macula, within ETDRS fields and extended peripheral fields. Ischemic areas were quantified using ImageJ to calculate nonperfusion index (NPI), CPI, and RPI. ciDME was determined on OCT. Correlations were analyzed using Pearson coefficients (r). Results DR severity correlated significantly with global NPI (r=0.56, p<0.0001) and across all retinal zones (r=0.35– 0.57). Both CPI (global: r=0.56, p<0.0001; zones: r=0.42–0.59) and RPI (global: r=0.55, p<0.0001; zones: r=0.40–0.59) showed similar associations. ciDME presence was also correlated with NPI (global: r=0.40, p=0.0014; zones: r=0.42–0.54), CPI (global: r=0.47, p=0.0001; zones: r=0.32–0.55), and RPI (global: r=0.46, p=0.0002; zones: r=0.33–0.54). Conclusions Cone- and rod-related retinal nonperfusion strongly correlate with DR severity and ciDME. UWF-FA may help identify high-risk eyes and guide surveillance of ischemia-related progression. Further studies are needed to define ischemic thresholds predictive of vision-threatening complications.
